Cellular immunity data after tick-borne encephalitis vaccination in HSCT patients
This data covers all relevent clinical data of the manuscript "Tick-borne encephalitis specific lymphocyte response after allogeneic hematopoietic stem cell transplantation predicts humoral immunity after vaccination" which describes the cellular part of the clinical study "Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients" (https://clinicaltrials.gov/ct2/show/NCT01991067): The aim of this prospective study was to assess lymphocyte proliferative and cytokine response prior and following TBE-immunization among patients after allogeneic hematopoietic stem cell transplantation (HSCT). Seventeen adult patients 11 to 13 months after HSCT and eight unvaccinated healthy adults received up to three TBE-vaccinations. Following in vitro stimulation with TBE antigen, lymphocyte proliferation and cytokine secretion (i.e., interleukin (IL) IL-2, IL-10, IL-13, TNF-alpha, IFN-gamma, GM-CSF) were analysed by thymidine incorporation assay and the Luminex system. Ten patients (59%) showed significant baseline TBE-specific lymphocyte proliferation (stimulation index (SI) >3) prior vaccination, but none of the unvaccinated controls (p=0.002). All patients with a TBE-specific antibody response after two vaccinations (at least 2-fold increase of neutralization test titres) exhibited a strong TBE-specific lymphocyte proliferative response at baseline (SI >10). Patients with sibling donors had a significantly stronger baseline TBE-specific lymphocyte proliferative and IL-13 cytokine response than patients with unrelated donors (p<0.05). In conclusion, a relevant proportion of patients showed TBE-specific lymphocyte proliferative and cytokine responses prior to vaccination after HSCT, which predicted the humoral response to the vaccine. Patients with vaccinated sibling donors were more likely to elicit a cellular immune response than patients with unrelated donors of unknown vaccination status.